Protagenic Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.29 Insider Own0.90% Shs Outstand17.61M Perf Week-7.35%
Market Cap10.60M Forward P/E- EPS next Y- Insider Trans24.32% Shs Float13.90M Perf Month-2.89%
Income-4.70M PEG- EPS next Q- Inst Own9.50% Short Float0.29% Perf Quarter-7.02%
Sales- P/S- EPS this Y-24.50% Inst Trans0.18% Short Ratio1.61 Perf Half Y-47.63%
Book/sh0.61 P/B0.98 EPS next Y- ROA- Target Price4.00 Perf Year-68.80%
Cash/sh0.50 P/C1.21 EPS next 5Y- ROE- 52W Range0.56 - 2.35 Perf YTD-56.52%
Dividend- P/FCF- EPS past 5Y6.50% ROI- 52W High-74.31% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low7.71% ATR0.05
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)41.83 Volatility8.43% 8.10%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume3.55 Prev Close0.60
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume24.87K Price0.60
Recom2.00 SMA20-3.00% SMA50-13.14% SMA200-44.13% Volume37,956 Change0.25%
Apr-26-22 08:15AM  
Nov-16-21 09:58AM  
Aug-30-21 09:15AM  
Aug-17-21 07:45AM  
Jul-23-21 04:21PM  
Jul-08-21 11:20AM  
Jul-06-21 06:17AM  
Jun-23-21 09:35AM  
Jun-16-21 09:15AM  
Apr-29-21 03:06PM  
Apr-26-21 08:58PM  
Dec-16-20 09:15AM  
Sep-08-20 12:10PM  
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Arrow Alexander K.Chief Financial OfficerMay 18Buy0.728,0005,760151,260May 18 05:11 PM
Arrow Alexander K.Chief Financial OfficerMay 17Buy0.7123,00016,330143,260May 18 05:11 PM